Clinical Trial Update: Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma [Phase 1]

View source ↗

Summary

Phase I clinical trial update for RC19D2 cell injection in recurrent or refractory diffuse large B-cell lymphoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• RC19D2 Cell Injection

Snippet

Sponsor: Beijing Yongtai Ruike Biotechnology Company Ltd | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 1 | Status: RECRUITING